This Preliminary Findings report has been provided to FDA CDER, CDRH, and Combination Products along with additional requisite info for FDA as we pursue FDA approval.

We are confident that, with the help of our partners like RD Abbott and other industry leaders, FiteBac’s K21 will be cleared for food contact, additional dental devices, several medical devices, and topical drug application by the end of October 2022.

FiteBac Drug K21 QAS Preliminary Findings

Using a two-pronged approach by partnering with manufacturers and distributors and by promoting FiteBac dentistry via direct-to-consumer advertising, we are poised to induce a specialty-wide evolution from traditional dentistry to antimicrobial dentistry.

Here is a link to our national ad:

FiteBac National Commercial 2022

This commercial has been aired in the Atlanta market on The Weather Channel, The History Channel, and Fox News. We achieved tremendous results with this test market and anticipate a significant ROI as we connect directly to the consumer throughout the U.S. with various TV, radio, and digital efforts.

Through partnerships with multiple international manufacturers, we released a line of antimicrobial additives, primed for inclusion in existing medical and dental device formulations.

Dentistry is the largest specialty in medicine and our antimicrobial products can provide novel benefits and protection to create a new standard of care for dental patients everywhere.

In 2021, we released a line of antimicrobial additives. For the first time ever, industrial and medical manufacturers now have the ability to strengthen their existing products by having them powered by FiteBac’s proprietary antimicrobial technology.

FiteBac K21 (another proprietary antimicrobial molecule) is present in our FDA-cleared cavity cleanser.

FiteBac medical device submissions for wound care will pursue antimicrobial claims, biofilm destruction claims, and healing assistance claims (including scar reduction). FiteBac, with the help of converters, have produced multiple wound care dressings, alginates, hydrocolloids, PLA, as well as adhesives with K18 all which have superior bactericidal efficacy. Why have an antimicrobial consumer bandage with BZK when a far more biocompatible K21 drug is available which could help reduce scarring and the healing process?

We have also included this report in our submission for EPA FIFRA registration. Upon complete registration, we can make our lab-proven applications available to the public: multiple plastics, resin systems, and coatings – all with improved durability, flexibility, and antimicrobial efficacy.

FiteBac has placed our technology into a myriad of rubbers, medical vinyls, and polymers.

1. Multiple Patents awarded in U.S., EU, China, Hong Kong
2. FiteBac Name and the red wave are trademarked in the U.S., EU, China, India, Brazil and more
3. All corporate legal entities and licensing matters are constructed, along with a Trust account and FiteBac Foundation
4. FDA and NIH recognize FiteBac K21 as a drug and IP, listed in the patent office as Kimmerling Holdings Group
5. Strong relationships with chemical suppliers like Siltech and Wacker, creating reassurance in a time of chemical/silane supply uncertainties
6. FiteBac has been working with a significant CRO Nucro-Technics in Canada. Animal studies will be coordinated with Nucro-Technics for drugs, devices, histology, analytics, etc. in preparation for licensing partners.
7. FiteBac’s international academic research team expands every month and provides more medical findings, furthering the reliability and proven effectiveness of our technology